Abstract
Influenza B represents a significant infection threat and can lead to substantial morbidity and mortality, particularly among young patients. To mitigate morbidity and mortality rates, it is imperative to implement appropriate vaccination and other preventive strategies.
Introduction
The global implementation of non-pharmaceutical interventions (NPIs)—such as masking, social distancing, and travel restrictions—to combat COVID-19 led to a dramatic, worldwide decline in other respiratory viruses like influenza and RSV. However, as regions returned to a state of "relative normalcy," the trajectory of these seasonal viruses became unpredictable. This study, published in the Virology Journal, examines the unexpected and severe surge of Influenza B in China during the 2021–2022 season, a period when COVID-19 cases were locally negligible. The researchers aimed to identify the causative agent behind a massive spike in "influenza-like illness" (ILI) observed in Beijing and across China, identifying who was most at risk and why some patients experienced severe outcomes.
Methods
The researchers employed a retrospective, multicenter observational approach utilizing three primary data sources:
- Local Clinic Data: Patient records from the Chinese PLA General Hospital and Beijing Tsinghua Changgung Hospital.
- National Surveillance: Publicly available influenza data from the China CDC.
- Multicenter Clinical Cohort: Data from 70 hospitalized patients with confirmed Influenza B across nine hospitals in five Chinese provinces.
Viral identification was performed using RT-PCR for COVID-19, Influenza A, and Influenza B. Genomic sequencing (IDseq™) was used to determine the specific lineage of the strain. Clinical data, including laboratory findings and imaging, were collected from the 70 hospitalized patients to identify markers of disease severity.
Key Insights
- The "Victoria" Monopoly: Influenza A was virtually non-existent during this period; 100% of the influenza cases were Influenza B, specifically the Victoria-like lineage.
- Age-Inverted Severity: Unlike COVID-19, which primarily affects the elderly, severe Influenza B cases were prevalent among younger individuals. The average age of those who died was 30 years, with four out of seven deaths occurring in children or adolescents (ages 1 to 15).
- The Lethal "Second Hit": Mortality was rarely due to the virus alone. Six out of the seven patients who died had secondary infections. Notably, all four pediatric/adolescent deaths were co-infected with Mycoplasma pneumoniae.
- Biomarkers of Severity: Indicators of severe disease included significantly lower platelet counts (thrombocytopenia) and sharply elevated levels of Lactate Dehydrogenase (LDH) and Creatine Kinase (CK), suggesting widespread organ injury.
Key Results
The study observed a dramatic increase in influenza activity starting in late 2021. In Beijing fever clinics, the influenza positivity rate climbed from approximately 8% in October 2021 to over 40% by late January 2022.
The broader trend across the study population showed a similar peak in both patient numbers and positivity rates during the winter months.
Within the hospitalized cohort, the mortality rate was 10% (7 out of 70). Severe patients showed a significant decrease in platelet counts ($P=0.008$) and significantly higher biochemical markers for liver injury (ALT/AST) and cell death (LDH) compared to non-severe patients. Genomic sequencing confirmed the circulating strain was closely related to the B/Florida/39/2018 strain.
Limitations
The study's retrospective design may introduce selection bias, as asymptomatic or non-hospitalized cases were not captured. Additionally, the small sample size for mortality (n=7) makes it difficult to definitively generalize risk factors for death. Further research is needed to understand the biological mechanisms that make younger patients more susceptible to severe outcomes when co-infected with pathogens like Mycoplasma.
Conclusion
As COVID-19 restrictions are relaxed, Influenza B poses a significant threat. The findings highlight the need for renewed focus on pediatric vaccination and vigilant monitoring for secondary bacterial infections to mitigate future outbreaks.
Summary updated